Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

   Completed · Phase 1 · Migraine

   NCT06578585 · H. Lundbeck A S · 4 U.S. investigators

   $842,567research payments

2. ADVENT Post Approval Study

   Active, not recruiting · Paroxysmal Atrial Fibrillation

   NCT06431815 · Boston Scientific Corporation · 24 U.S. investigators

   $838,222research payments

3. A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation

   Completed · Not applicable · Persistent Atrial Fibrillation

   NCT05443594 · Boston Scientific Corporation · 36 U.S. investigators

   $836,351research payments

4. Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

   Recruiting · Chronic Low-back Pain

   NCT06827262 · Boston Scientific Corporation · 13 U.S. investigators

   $836,138research payments

5. A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

   Recruiting · Phase 3 · Areata Alopecia

   NCT05723198 · Eli Lilly and Company · 37 U.S. investigators

   $829,933research payments

6. Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

   Active, not recruiting · Parkinson's Disease (PD)

   NCT06107426 · AbbVie Inc. · 25 U.S. investigators

   $828,308research payments

7. Congenital Athymia Patient Registry

   Recruiting · Complete DiGeorge Anomaly

   NCT05329935 · Sumitomo Pharma America, Inc. · 8 U.S. investigators

   $828,285research payments

8. GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

   Recruiting · Not applicable · Stroke

   NCT03821129 · W. L. Gore & Associates, Inc. · 41 U.S. investigators

   $823,267research payments

9. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

   Completed · Phase 3 · Open-Angle Glaucoma

   NCT03850782 · AbbVie Inc. · 26 U.S. investigators

   $822,096research payments

10. Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

    Terminated · Not applicable · Diabetic Foot Ulcer

    NCT06455475 · Royal Biologics, Inc. · 15 U.S. investigators

    $816,982research payments

11. Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

    Completed · Phase 2, Phase 3 · COVID-19

    NCT04762680 · Sanofi Pasteur Inc. · 16 U.S. investigators

    $815,057research payments

12. Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

    Terminated · Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

    NCT06014541 · Ionis Pharmaceuticals, Inc. · 6 U.S. investigators

    $813,366research payments

13. Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

    Completed · Phase 2 · Insomnia

    NCT05423717 · Idorsia Pharmaceuticals US Inc · 9 U.S. investigators

    $811,479research payments

14. A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

    Completed · Phase 3 · Primary Biliary Cholangitis

    NCT06383403 · Ipsen Bioscience Inc. · 25 U.S. investigators

    $810,200research payments

15. A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

    Terminated · Phase 2 · Panic Disorder

    NCT05941442 · AbbVie Inc. · 28 U.S. investigators

    $810,097research payments

16. A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

    Active, not recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT03336333 · Beone Medicines Ltd. · 15 U.S. investigators

    $809,965research payments

17. Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

    Recruiting · Phase 2 · Chronic Lymphocytic Leukemia

    NCT06849713 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $808,945research payments

18. Registry for Participants With Short Bowel Syndrome

    Active, not recruiting · Short Bowel Syndrome

    NCT01990040 · Takeda Pharmaceuticals U.S.A., Inc. · 35 U.S. investigators

    $805,826research payments

19. A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

    Active, not recruiting · Phase 3 · Breast Neoplasms

    NCT04975308 · Eli Lilly and Company · 21 U.S. investigators

    $803,437research payments

20. A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

    Active, not recruiting · Phase 3 · Carcinoma, Non-Small-Cell Lung

    NCT04819100 · Eli Lilly and Company · 8 U.S. investigators

    $803,188research payments

21. Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

    Active, not recruiting · Phase 1 · Food Allergy

    NCT06369467 · Regeneron Pharmaceuticals, Inc. · 5 U.S. investigators

    $802,530research payments

22. A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

    Enrolling by invitation · Phase 3 · Atopic Dermatitis

    NCT05735483 · Eli Lilly and Company · 19 U.S. investigators

    $800,680research payments

23. A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

    Completed · Phase 4 · Facial Contouring

    NCT06783621 · AbbVie Inc. · 10 U.S. investigators

    $799,791research payments

24. Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

    Enrolling by invitation · Phase 3 · Migraine Prophylaxis

    NCT05707949 · AbbVie Inc. · 57 U.S. investigators

    $798,085research payments

25. A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

    Completed · Phase 2 · Respiratory Syncytial Virus

    NCT06097299 · ModernaTX, Inc. · 43 U.S. investigators

    $795,479research payments

26. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

    Recruiting · Phase 1 · Advanced Solid Tumor

    NCT06120283 · Beone Medicines USA, Inc. · 7 U.S. investigators

    $793,503research payments

27. Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

    Active, not recruiting · Phase 3 · Breast Cancer

    NCT03155997 · Eli Lilly and Company · 103 U.S. investigators

    $789,401research payments

28. A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

    Recruiting · Phase 3 · Depression

    NCT04777357 · AbbVie Inc. · 58 U.S. investigators

    $784,151research payments

29. A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

    Active, not recruiting · Phase 1, Phase 2 · Melanoma

    NCT06305247 · Ipsen Pharma Sas · 10 U.S. investigators

    $783,162research payments

30. A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

    Recruiting · Phase 2 · Narcolepsy Type 2

    NCT06952699 · Takeda Pharmaceuticals U.S.A., Inc. · 11 U.S. investigators

    $780,014research payments

31. Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

    Active, not recruiting · Cerebral Adrenoleukodystrophy (CALD)

    NCT02698579 · Genetix Biotherapeutics Inc · 6 U.S. investigators

    $778,026research payments

32. Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System

    Recruiting · Intracranial Hemorrhage

    NCT06649097 · Irras USA, Inc. · 1 U.S. investigator

    $775,000research payments

33. The THOR IDE Study

    Recruiting · Not applicable · Peripheral Artery Disease

    NCT05916950 · Philips North America LLC · 23 U.S. investigators

    $772,207research payments

34. Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

    Completed · Phase 1 · Cutaneous Squamous Cell Carcinoma

    NCT03889912 · Regeneron Pharmaceuticals, Inc. · 10 U.S. investigators

    $768,074research payments

35. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

    Completed · Phase 3 · Esophageal Squamous Cell Carcinoma (ESCC)

    NCT03430843 · Beone Medicines Ltd. · 9 U.S. investigators

    $768,068research payments

36. A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

    Active, not recruiting · Phase 2 · Non Small Cell Lung Cancer

    NCT06465329 · Regeneron Pharmaceuticals, Inc. · 12 U.S. investigators

    $766,149research payments

37. ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

    Terminated · Bladder Cancer

    NCT06026332 · Ferring Pharmaceuticals As · 32 U.S. investigators

    $765,801research payments

38. Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

    Recruiting · Phase 2 · Metastatic Colorectal Cancer

    NCT05854498 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $758,480research payments

39. A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

    Completed · Phase 3 · Phenylketonuria

    NCT05166161 · Ptc Therapeutics, Inc. · 8 U.S. investigators

    $754,107research payments

40. INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone

    Recruiting · Not applicable · Wound Heal

    NCT06606210 · Convatec Inc. · 7 U.S. investigators

    $752,327research payments

41. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

    Active, not recruiting · Phase 1 · Breast Cancer

    NCT06257264 · Beone Medicines Ltd. · 6 U.S. investigators

    $749,314research payments

42. A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Recruiting · Phase 2 · Chronic Lymphocytic Leukemia

    NCT06588478 · Eli Lilly and Company · 20 U.S. investigators

    $742,849research payments

43. A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

    Active, not recruiting · Phase 1 · Diffuse Large B-Cell Lymphoma

    NCT05512390 · AbbVie Inc. · 8 U.S. investigators

    $741,842research payments

44. A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

    Recruiting · Phase 3 · Stereotypical Prolonged Seizures

    NCT05077904 · UCB SA · 55 U.S. investigators

    $740,157research payments

45. An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

    Active, not recruiting · Phase 3 · Biliary Atresia

    NCT05426733 · Albireo Pharma, Inc. · 20 U.S. investigators

    $739,521research payments

46. A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

    Completed · Phase 3 · Hidradenitis Suppurativa

    NCT04901195 · UCB SA · 27 U.S. investigators

    $738,404research payments

47. SAfety of Regional Citrate Anticoagulation (SARCA Study)

    Completed · Phase 3 · Acute Kidney Injury

    NCT05339139 · Fresenius USA Marketing, Inc. · 10 U.S. investigators

    $738,094research payments

48. A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

    Completed · Phase 1 · Cachexia

    NCT05865535 · Aveo Pharmaceuticals, Inc. · 12 U.S. investigators

    $737,176research payments

49. A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

    Active, not recruiting · Phase 3 · In-Stent Restenosis

    NCT04647253 · Boston Scientific Corporation · 41 U.S. investigators

    $736,754research payments

50. Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

    Completed · Phase 3 · Partial Epilepsy

    NCT05067634 · Sk Life Science, Inc. · 18 U.S. investigators

    $735,957research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.